• Explore /
  • Poster
  • / KEYNOTE-062: phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

KEYNOTE-062: phase 3 study of pembrolizumab alone or in combination with chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma.

Abstract Poster

Authors

Josep Tabernero

Josep Tabernero

Vall d'Hebron University Hospital, Barcelona, Spain

Josep Tabernero , Yung-Jue Bang , Charles S. Fuchs , Atsushi Ohtsu , Uma Kher , Baohoang Lam , Minori Koshiji , Eric Van Cutsem

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2016 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal (Noncolorectal) Cancer

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02494583

Citation

J Clin Oncol 34, 2016 (suppl; abstr TPS4138)

DOI

10.1200/JCO.2016.34.15_suppl.TPS4138

Abstract #

TPS4138

Poster Bd #

126b

Abstract Disclosures

Similar Posters

First Author: Josep Tabernero

First Author: Zev A. Wainberg

First Author: Zev A. Wainberg

First Author: Yelena Y. Janjigian